GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Biotech Acquisition Co (NAS:BIOTU) » Definitions » ROE %

BIOTU (Biotech Acquisition Co) ROE % : 2.32% (As of Sep. 2022)


View and export this data going back to 2021. Start your Free Trial

What is Biotech Acquisition Co ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Biotech Acquisition Co's annualized net income for the quarter that ended in Sep. 2022 was $5.04 Mil. Biotech Acquisition Co's average Total Stockholders Equity over the quarter that ended in Sep. 2022 was $217.54 Mil. Therefore, Biotech Acquisition Co's annualized ROE % for the quarter that ended in Sep. 2022 was 2.32%.

The historical rank and industry rank for Biotech Acquisition Co's ROE % or its related term are showing as below:

BIOTU' s ROE % Range Over the Past 10 Years
Min: -6.77   Med: -6.77   Max: 3.81
Current: 3.81

During the past 2 years, Biotech Acquisition Co's highest ROE % was 3.81%. The lowest was -6.77%. And the median was -6.77%.

BIOTU's ROE % is not ranked
in the Diversified Financial Services industry.
Industry Median: 0.64 vs BIOTU: 3.81

Biotech Acquisition Co ROE % Historical Data

The historical data trend for Biotech Acquisition Co's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biotech Acquisition Co ROE % Chart

Biotech Acquisition Co Annual Data
Trend Dec20 Dec21
ROE %
- -6.77

Biotech Acquisition Co Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
ROE % Get a 7-Day Free Trial Premium Member Only 5.64 -14.11 9.12 17.69 2.32

Competitive Comparison of Biotech Acquisition Co's ROE %

For the Shell Companies subindustry, Biotech Acquisition Co's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biotech Acquisition Co's ROE % Distribution in the Diversified Financial Services Industry

For the Diversified Financial Services industry and Financial Services sector, Biotech Acquisition Co's ROE % distribution charts can be found below:

* The bar in red indicates where Biotech Acquisition Co's ROE % falls into.



Biotech Acquisition Co ROE % Calculation

Biotech Acquisition Co's annualized ROE % for the fiscal year that ended in Dec. 2021 is calculated as

ROE %=Net Income (A: Dec. 2021 )/( (Total Stockholders Equity (A: Dec. 2020 )+Total Stockholders Equity (A: Dec. 2021 ))/ count )
=-6.865/( (0.02+202.851)/ 2 )
=-6.865/101.4355
=-6.77 %

Biotech Acquisition Co's annualized ROE % for the quarter that ended in Sep. 2022 is calculated as

ROE %=Net Income (Q: Sep. 2022 )/( (Total Stockholders Equity (Q: Jun. 2022 )+Total Stockholders Equity (Q: Sep. 2022 ))/ count )
=5.044/( (216.913+218.174)/ 2 )
=5.044/217.5435
=2.32 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Sep. 2022) net income data. ROE % is displayed in the 30-year financial page.


Biotech Acquisition Co  (NAS:BIOTU) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Sep. 2022 )
=Net Income/Total Stockholders Equity
=5.044/217.5435
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(5.044 / 0)*(0 / 230.9065)*(230.9065 / 217.5435)
=Net Margin %*Asset Turnover*Equity Multiplier
=N/A %*0*1.0614
=ROA %*Equity Multiplier
=N/A %*1.0614
=2.32 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Sep. 2022 )
=Net Income/Total Stockholders Equity
=5.044/217.5435
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (5.044 / 5.044) * (5.044 / -0.988) * (-0.988 / 0) * (0 / 230.9065) * (230.9065 / 217.5435)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1 * -5.1053 * N/A % * 0 * 1.0614
=2.32 %

Note: The net income data used here is four times the quarterly (Sep. 2022) net income data. The Revenue data used here is four times the quarterly (Sep. 2022) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Biotech Acquisition Co ROE % Related Terms

Thank you for viewing the detailed overview of Biotech Acquisition Co's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Biotech Acquisition Co Business Description

Traded in Other Exchanges
N/A
Address
545 West 25th Street, 20th Floor, New York, NY, USA, 10001
Website
Biotech Acquisition Co is a blank check company.
Executives
Albert F Hummel director, officer: Chief Investment Officer PO BOX 3407, RANCHO SANTA FE CA 92067
Biotech Sponsor Llc 10 percent owner 545 W. 25TH ST., 20TH FLOOR, NEW YORK NY 10001
Bruno Montanari director 545 WEST 25TH STREET, 20TH FLOOR, NEW YORK NY 10001
Ivan Jarry officer: Chief Operating Officer 545 WEST 25TH STREET, 20TH FLOOR, NEW YORK NY 10001
Paul Bernard director 545 WEST 25TH STREET 20TH FL, NEW YORK NY 10001
Aaron Kim director 545 WEST 25TH STREET 20TH FL, NEW YORK NY 10001
Michael Schleifer director, 10 percent owner, officer: Chief Executive Officer 545 WEST 25TH STREET 20TH FLOOR, NEW YORK NY 10001
Thomas Fratacci officer: CFO & Treasurer 545 WEST 25TH STREET, 20TH FLOOR, NEW YORK NY 10001

Biotech Acquisition Co Headlines

From GuruFocus

Biotech Acquisition Company Announces Liquidation

By GlobeNewswire GlobeNewswire 02-02-2023